722O Randomised phase II trial of olaparib compared to weekly paclitaxel or olaparib plus cediranib in patients with platinum-resistant ovarian cancer (OCTOVA)

Authors :: Gordon C Jayson
Shibani Nicum
Andrew R Clamp
Jane Holmes
L Collins
Marcia Hall
Stan B. Kaye
Naomi McGregor
R.M. Glasspool
R Kristeleit
Anita Mansouri
R. Roux
Agnieszka Michael
R. Dunn
Iain A. McNeish
Sushmita Banerjee
Source :: Annals of Oncology. 32:S725-S726
Publication Year :: 2021
Publisher :: Elsevier BV, 2021.

Subjects :: Oncology
medicine.medical_specialty
business.industry
Weekly paclitaxel
Hematology
medicine.disease
Olaparib
Cediranib
chemistry.chemical_compound
chemistry
Internal medicine
medicine
In patient
business
Ovarian cancer
Platinum resistant
medicine.drug

Full Text Access

Tools